Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LABCORP HOLDINGS INC.LH · Entity 1277 | Director | February 11, 2026 | February 13, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LABCORP HOLDINGS INC.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,571 |
Reported balance
After 2026-02-11 transaction · row 1
1 source rowRow 1 · 2026-02-11 · Exercise / conversion · Acquired 897 · Balance 2,571 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 773 |
Reported balance
After 2026-02-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-11 · Exercise / conversion · Disposed 897 · Balance 773 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2: The Restricted Stock Units vested fully on February 11, 2026. F3: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
F2: The Restricted Stock Units vested fully on February 11, 2026.
F3: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
Merck & Co., Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 34,944.9417 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 1,853.0997 · Balance 34,944.9417 F1: 1-for-1 F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3: Holdings include shares acquired in dividend reinvestment transactions. |
| Common StockSEC Table I · non-derivative | Direct | 100 |
Reported balance
Holding disclosure · report date 2026-05-29 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 100 |
Filing footnotes · ownership attribution and instrument terms
F1: 1-for-1
F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
F3: Holdings include shares acquired in dividend reinvestment transactions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 2, 2026 18:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 1,853.0997 | $118.72 | $220,000.00 |
DisclosureSEC source: 0000310158-26-000157 · form4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,944.9417 Underlying: Common Stock · 1,853.0997 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 18:03 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000079 · form4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 773 Underlying: Common Stock · 897 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2026. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 18:03 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000079 · form4.xml · nonDerivative · entry 1 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 16:24 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 733 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000057 · form4.xml · derivative · entry 1 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,670 Underlying: Common Stock · 733 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 10, 2027. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 10, 2027. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 17:18 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,863.0921 | $76.84 | $220,000.00 |
DisclosureSEC source: 0001127602-25-016365 · form4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,990.803 Underlying: Common Stock · 2,863.0921 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 13:26 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004520 · form4.xml · derivative · entry 1 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897 Underlying: Common Stock · 897 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2026. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 13:38 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 944 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003700 · form4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 944 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested fully on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vested fully on February 6, 2025. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 13:38 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 944 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-003700 · form4.xml · nonDerivative · entry 1 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · balance_after: Amount includes 13 shares previously reported on the reporting person's Form 3 filed on June 7, 2023 that were inadvertently omitted from the reporting person's Form 4 filed on June 10, 2024. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 12:52 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 717 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018228 · form4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944 Underlying: Common Stock · 717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on June 6, 2024. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on June 6, 2024. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 12:52 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 717 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018228 · form4.xml · nonDerivative · entry 1 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 18:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 1,752.4295 | $125.54 | $220,000.00 |
DisclosureSEC source: 0001127602-24-017592 · form4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,233.6119 Underlying: Common Stock · 1,752.4295 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 17:53 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 944 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003898 · form4.xml · derivative · entry 1 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,661 Underlying: Common Stock · 944 shares Expires not disclosed F1 · derivative.exercise_price: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 75 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 12:24 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 642 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018221 · form4.xml · derivative · entry 1 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 642 Underlying: Common Stock · 642 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on June 6, 2024. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on June 6, 2024. Read SEC document |
| May 26, 2023 Filed May 31, 2023 18:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 1,980.7329 | $111.07 | $220,000.00 |
DisclosureSEC source: 0001127602-23-017183 · form4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,797.5164 Underlying: Common Stock · 1,980.7329 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,363.5582 | $93.08 | $220,000.00 |
DisclosureSEC source: 0001127602-22-016169 · form4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,152.0155 Underlying: Common Stock · 2,363.5582 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 17:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,635.3933 | $75.89 | $200,000.00 |
DisclosureSEC source: 0001127602-21-018661 · form4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,522.4763 Underlying: Common Stock · 2,635.3933 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 21:12 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,477.7007 | $80.72 | $200,000.00 |
DisclosureSEC source: 0001127602-20-018491 · form4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,361.5907 Underlying: Common Stock · 2,477.7007 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 21:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,335.5637 | $79.21 | $185,000.00 |
DisclosureSEC source: 0001104659-19-033850 · a4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,505.7267 Underlying: Common Stock · 2,335.5637 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2018 Filed May 29, 2018 21:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 3,130.8174 | $59.09 | $185,000.00 |
DisclosureSEC source: 0001225208-18-009925 · doc4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,857.2744 Underlying: Common Stock · 3,130.8174 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 26, 2017 Filed May 30, 2017 21:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,618.6075 | $64.92 | $170,000.00 |
DisclosureSEC source: 0001225208-17-010556 · doc4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,482.3855 Underlying: Common Stock · 2,618.6075 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 27, 2016 Filed May 31, 2016 19:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 3,009.915 | $56.48 | $170,000.00 |
DisclosureSEC source: 0001225208-16-034171 · doc4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,719.549 Underlying: Common Stock · 3,009.915 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 01, 2015 Filed Sep 2, 2015 19:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 1,665.7148 | $52.53 | $87,500.00 |
DisclosureSEC source: 0001225208-15-017864 · doc4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,665.7148 Underlying: Common Stock · 1,665.7148 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.